CRVS
Corvus Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.03Close
$749.2MMarket cap
$6.50 – $25.5252-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 14 · weaker than 86% of stocks over 12 months
- Far from its high 61% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
61%
1wk
down 4.7%
price change
1mo
down 12.9%
price change
12-month return
up 29%
market up 11% ·
its own up 20%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
12.2×
price / book
Earnings yield
down 5.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 33%
return on equity
Free cash margin
—
-$33.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.9%
$0.60 a day · 2×ATR $8.84
RS
14 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.54
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- 200-day average rising for a month: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 10.0% over the year, from 68m to 75m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$43.8M | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M |
| Net income | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
| Earnings per share | -$0.20 | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.19 |
| Free cash flow | -$34.9M | -$36.7M | -$27.3M | -$24.0M | -$25.4M | -$33.0M |
| Cash | $16.5M | $63.5M | $13.2M | $12.6M | $8.7M | $4.6M |
| Shareholders' equity | $72.1M | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M |
| Shares outstanding | 28.37m | 46.55m | 46.55m | 49.04m | 67.90m | 74.70m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 25, 2025 | Annual ↗ | Dec 31, 2024 | 84d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 22, 2026 | Director or officer change ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 14, 2026 | Regulation FD · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Apr 23, 2026 | Director or officer change ↗ |
| Mar 13, 2026 | Material agreement ↗ |
| Mar 12, 2026 | Results ↗ |
| Jan 23, 2026 | Other events ↗ |
| Jan 20, 2026 | Other events ↗ |
| Jan 20, 2026 | Regulation FD · Other events ↗ |
| Nov 4, 2025 | Results ↗ |